Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce that it has received a second payment under the exclusive Evaluation and License Option Agreement with the leading global animal health company Zoetis Inc. (NYSE:ZTS) for Detach(TM), Anatara's non-antibiotic anti-infective product.
NDF Research yesterday released its initiation report on Anatara Lifesciences Ltd (ASX:ANR). The report provided a valuation at $2.22 per share base case and $5.94 per share optimistic case using a DCF approach, with a target price of $4.00 per share sitting midpoint of their valuation range.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, announced that it has entered into a strategic collaboration and licensing agreement with AGC Asahi Glass (AGC) (TYO:5201), a world-leading manufacturer of glass, chemicals, high-tech materials and biopharmaceuticals.
Alvogen has launched the first generic equivalent to Tamiflu(R) (oseltamivir phosphate) capsules in the United States. Alvogen expects the generic equivalent to Tamiflu(R) capsules to deliver significant savings for patients and health providers of up to $500 million during this upcoming season. The product is available in three strengths (30 mg, 45 mg and 75 mg).
Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its updated investor presentation.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the company's AGM Presentation held on 15 November 2016.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the company's latest Chairman's Address to Shareholders at 2016 AGM.
